Saudi Central Bank Buys 18,938 Shares of Edwards Lifesciences Corporation $EW

Saudi Central Bank increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 88.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,358 shares of the medical research company’s stock after acquiring an additional 18,938 shares during the quarter. Saudi Central Bank’s holdings in Edwards Lifesciences were worth $3,651,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Brighton Jones LLC acquired a new position in Edwards Lifesciences in the 4th quarter worth $266,000. NewEdge Advisors LLC increased its position in shares of Edwards Lifesciences by 8.1% during the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock worth $2,787,000 after purchasing an additional 2,665 shares during the last quarter. Sei Investments Co. increased its holdings in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock worth $32,285,000 after buying an additional 58,988 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of Edwards Lifesciences by 277.7% during the 2nd quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in Edwards Lifesciences by 0.4% in the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after buying an additional 1,065 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,045 shares of company stock valued at $457,749 in the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on EW shares. UBS Group started coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price for the company. Evercore reissued an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Mizuho lifted their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Finally, Piper Sandler reiterated an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $90.00 on Monday. The company has a market capitalization of $51.82 billion, a PE ratio of 51.72, a P/E/G ratio of 2.36 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $89.73 and a 200 day simple moving average of $85.56. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.